Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (BOT), an ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the ...

Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer The ...

Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC ...

Endometrial cancer represents the most prevalent gynecologic malignancy in high-income regions, where its management conventionally hinges on ...

Study reveals how Cytovale's IntelliSep® sepsis test enables early sepsis risk stratification and more precise documentation, increasing SEP-1 compliance by 29% SAN FRANCISCO and SALT LAKE CITY, Sept.

(L) Giles Robinson, MD, St. Jude Division of Neuro-oncology director, Department of Oncology, co-corresponding author on the Neuro-Oncology and Cancer Research studies and (R) Xin Zhou, PhD, St. Jude ...

Castle Biosciences will present TissueCypher Barrett’s Esophagus test data at DDW 2025, emphasizing risk stratification and personalized patient management. Castle Biosciences, Inc. will present new ...

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology The ideas and opinions ...